Kelainan Hemostasis pada pasien Covid-19

Penulis

  • Hartono Kahar Fakultas Kedokteran Universitas Muhammadiyah Surabaya
  • Nabil Salim Fakultas Kedokteran Universitas Muhammadiyah Surabaya

Abstrak

Abstract
Coagulopathy in SARS-CoV-2 (Covid-19) patients is an emerge situation to treat because it
increases morbidity and mortality. Increased levels of tPA indicate spontaneous fibrinolysis as
well as a significant increase in Fibrin / Fibrinogen degradation product (FDP) and D-dimer
in Covid-19 patients. The invasion of the Covid-19 virus into the endothelial blood vessels
causes endothelial cell dysfunction, a decrease in the fibrinolytic function of the cells, which
predisposes to thrombus formation. In severe cases, IL-6 which is also released due to
endothelial damage predisposes to Sepsis-Induced Coagulopathy (SIC) and Disseminated
Intravascular Coagulation (DIC).
Keywords: SARS-CoV-2 (Covid-19), Coagulopathy, SIC, DIC.

Referensi

Seheult JN, Seshadri A, Neal MD. Fibrinolysis Shutdown and Thrombosis in Severe COVID-19.

J Am Coll Surg [Internet]. 2020;231(2):203–4. Available from:

https://doi.org/10.1016/j.jamcollsurg.2020.05.021

Eltayeb N, Abdulgader A, Hamza A, Hamza A, Awadelkareem H, Fadl O, et al. Venous

Thromboembolism in Covid-19 ICU Patients : A Narrative Review. 2020;3(July):35–43.

Umemura Y, Yamakawa K, Kiguchi T, Nishida T, Kawada M, Fujimi S. Hematological

Phenotype of COVID-19-Induced Coagulopathy: Far from Typical Sepsis-Induced

Coagulopathy. J Clin Med. 2020;9(9):2875.

Gale AJ. åŸºå› çš„æ”¹å˜NIH Public Access. Bone. 2008;23(1):1–7.

Wolberg AS. NIH Public Access. 2013;114(2):275–85.

Kurniawan LB. Clinical Pathology and Majalah Patologi Klinik Indonesia dan Laboratorium

Medik. J Indones [Internet]. 2006;21(3):261–5. Available from:

http://journal.unair.ac.id/download-fullpapers-IJCPML-12-3-08.pdf

Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New Fundamentals in hemostasis. Physiol

Rev. 2013;93(1):327–58.

Masi P, Hékimian G, Lejeune M, Chommeloux J, Desnos C, Pineton De Chambrun M, et al.

Systemic inflammatory response syndrome is a major contributor to COVID-19-associated

coagulopathy: Insights from a prospective, single-center cohort study. Circulation.

;142(6):611–4.

Zuo Y. 済無No Title No Title. Sereal Untuk. 2018;51(1):51.

Ahmed S, Zimba O, Gasparyan AY. Thrombosis in Coronavirus disease 2019 (COVID-19)

through the prism of Virchow’s triad. Clin Rheumatol. 2020;39(9):2529–43.

Bronić A, Herak DC, Margetić S, Milić M. Croatian society of medical biochemistry and

laboratory medicine: National recommendations for blood collection, processing, performance

and reporting of results for coagulation screening assays prothrombin time, activated partial

thromboplastin time, thrombin time, fibrinogen and D-dimer. Biochem Medica. 2019;29(2):1–

Aggarwal M, Dass J, Mahapatra M. Hemostatic Abnormalities in COVID-19: An Update. Indian

J Hematol Blood Transfus [Internet]. 2020;36(4):616–26. Available from:

https://doi.org/10.1007/s12288-020-01328-2

Wright FL. Fibrinolytic shutdown correlation wuth thromboembolism. Ann Oncol.

;(January):19–20.

Unduhan

Diterbitkan

2021-04-06